At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 245 enrolled
Drug / intervention
Netarsudil ophthalmic solution 0.02% +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-masked, Randomized, Multi-center, Parallel-group, 4-week Study Evaluating the Efficacy and Safety of Once Daily Netarsudil Ophthalmic Solution 0.02% Compared to Twice Daily Ripasudil Hydrochloride Hydrate Ophthalmic Solution 0.4% in Japanese Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
In Brief
A Phase 3 clinical trial evaluating Netarsudil ophthalmic solution 0.02% and Ripasudil hydrochloride hydrate ophthalmic solution 0.4% for Primary Open Angle Glaucoma and Ocular Hypertension. Completed, enrolled 245 participants across 1 site.
Detailed Summary
A Phase 3 Study Comparing the Efficacy and Safety of Netarsudil Ophthalmic Solution 0.02% QD to Ripasudil Hydrochloride Hydrate Ophthalmic Solution 0.4% BID, for Treatment of Primary Open-Angle Glaucoma or Ocular Hypertension Over A 4-Week Period.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrimary Open Angle Glaucoma, Ocular Hypertension
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedNov 2020
Enrollment StartNov 2020
Primary CompletionJul 2021
Study CompletionJul 2021
TodayJul 2026
First PostedNov 6, 2020
Enrollment StartNov 30, 2020
Primary CompletionJul 9, 2021
Study CompletionJul 30, 2021
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 5.7 years ago
Interventions
Netarsudil ophthalmic solution 0.02%drug
Topical sterile ophthalmic solution Other Name: Rhopressa®
Ripasudil hydrochloride hydrate ophthalmic solution 0.4%drug
Other Name: Glanatec®